OCEAN STAR TECH (08297) announces interim results, with a net loss of HKD 414,000 attributable to shareholders, a year-on-year decrease of 96.76%.
Haina Xingkong Technology (08297) released its interim results for the 6 months ending on September 30, 2025. The company achieved a profit of 14.78 million Hong Kong dollars, representing an increase of 5.68% year-on-year. The loss attributable to owners of the company for the period narrowed to 414,000 Hong Kong dollars, a decrease of 96.76% year-on-year. The basic loss per share was 0.03 Hong Kong cents.
OCEAN STAR TECH (08297) announced its interim performance for the six months ending September 30, 2025. The company earned a profit of 14.78 million Hong Kong dollars, an increase of 5.68% compared to the same period last year. The loss attributable to shareholders of the company was 414,000 Hong Kong dollars, a decrease of 96.76% compared to the same period last year, with a basic loss per share of 0.03 Hong Kong cents.
Looking ahead, the group is committed to implementing a "dual-track" growth strategy to mitigate market volatility and restore shareholder value. Through proactive cost management and lease renegotiations, we will continue to streamline our core underwear retail network and accelerate the development of our diversified business areas. Through leveraging new strategic partnerships, the group aims to broaden its sources of income, establish a more robust business foundation, and prepare for the expected complex geopolitical and economic changes in the remaining time of the 2025/26 fiscal year.
Related Articles

Haisco Pharmaceutical Group (002653.SZ): HSK50042 tablet obtains clinical trial approval for new indications.

Ningbo Sanxing Medical Electric's subsidiary signs a 9.49 billion yuan overseas operating contract.

Zhejiang Medicine (600216.SH): ARX305 initiates Phase II clinical trial.
Haisco Pharmaceutical Group (002653.SZ): HSK50042 tablet obtains clinical trial approval for new indications.

Ningbo Sanxing Medical Electric's subsidiary signs a 9.49 billion yuan overseas operating contract.

Zhejiang Medicine (600216.SH): ARX305 initiates Phase II clinical trial.

RECOMMEND





